systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.38109/2075-082X-2024-3-23-30systhiper-825Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLEКлиническое течение и прогноз пациентов с идиопатической легочной гипертензией после перенесенной COVID-19Clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension after COVID-19https://orcid.org/0000-0002-7904-6735ШарияА. М.ShariyaA. M.

Арчил Мерабович Шария, лаборант-исследователь

Институт клинической кардиологии им. А.Л. Мясникова

121552; ул. Академика Чазова, д. 15 а; Москва

Archil M. Shariya, laboratory research assistant

121552; St. Academician Chazova, 15 a; Moscow

achishar@yandex.ruhttps://orcid.org/0000-0002-9041-3604ВалиеваЗ. С.ValievaZ. S.

Зарина Солтановна Валиева, д. м. н., старший научный сотрудник

Институт клинической кардиологии им. А.Л. Мясникова; отдел легочной гипертензии и заболеваний сердца

121552; ул. Академика Чазова, д. 15 а; Москва

Zarina S. Valieva, Dr. Of Sci. (Med.), Senior Researcher

A.L. Myasnikov Institute of Clinical Cardiology; Department of Pulmonary Hypertension and Heart Diseases

121552; St. Academician Chazova, 15 a; Moscow

https://orcid.org/0000-0002-0292-0236ЕнМ. Ю.EnM. Yu.

Маргарита Юрьевна Ен, лаборант-исследователь

Институт клинической кардиологии им. А.Л. Мясникова

121552; ул. Академика Чазова, д. 15 а; Москва

Margarita Yu. En, laboratory research assistant

A.L. Myasnikov Institute of Clinical Cardiology

121552; St. Academician Chazova, 15 a; Moscow

https://orcid.org/0000-0002-9022-8097МартынюкТ. В.MartynyukT. V.

Тамила Витальевна Мартынюк, д. м. н., руководитель отдела, профессор

Институт клинической кардиологии им. А.Л. Мясникова; ФДПО; кафедра кардиологии

121552; ул. Академика Чазова, д. 15 а; 117513; ул. Островитянова д. 1, г; Москва

тел.: 8-495-414-64-50

Tamila V. Martynyuk, Dr. Of Sci. (Med.), Head of the Department, Professor

A.L. Myasnikov Institute of Clinical Cardiology; Pulmonary Hypertension and Heart Diseases; Faculty of Continuing Professional Education; Department of Cardiology

121552; St. Academician Chazova, 15 a; Moscow

tel.: 8-495-414-64-50

trukhiniv@mail.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Министерства здравоохранения Российской ФедерацииРоссияE.I. Chazov National Medical Research Center of cardiologyRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Министерства здравоохранения Российской Федерации; РМИМУ им. Н.И. ПироговаРоссияE.I. Chazov National Medical Research Center of cardiology; N.I. Pirogov Russian National Research Medical UniversityRussian Federation2024271020242132330Copyright © Шария А.М., Валиева З.С., Ен М.Ю., Мартынюк Т.В., 20242024Шария А.М., Валиева З.С., Ен М.Ю., Мартынюк Т.В.Shariya A.M., Valieva Z.S., En M.Y., Martynyuk T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/825

   Новая коронавирусная инфекция (COVID-19) – инфекционное заболевание, вызываемое вирусом из семейства коронавирусов (SARS-CoV). Данный вирус имеет в своем патогенезе множество факторов, влияющих на функцию ПЖ и легочную гемодинамику, что может негативно отразиться на клиническом течении ИЛГ. По итогам нашего исследования факт перенесенной COVID-19 у пациентов с ИЛГ приводит к некоторым изменениям лабораторно-инструментальных показателей. Однако не выявлено значительного влияния COVID-19 на модификацию риска в течение года после перенесенной инфекции. Этот результат можно объяснить сочетанием патофизиологических особенностей основного заболевания и защитным эффектом постоянно принимаемой ЛАГ-специфической и антикоагулянтной терапии.

   The coronavirus disease of 2019 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus (SARS-CoV-2). This virus has many factors in its pathogenesis that affect the function of the right ventricle and pulmonary hemodynamics, which can negatively influence the clinical course of IPAH. According to the results of our study, the fact of getting over COVID-19 in patients with IPAH leads to some changes in laboratory and instrumental parameters. But no significant effect of COVID-19 on risk modification during the year was detected. This result can be explained by a combination of pathophysiological features of the pulmonary hypertension and the protective effect of constantly taken PAH-specific and anticoagulant therapy.

идиопатическая легочная гипертензиялегочная артериальная гипертензияCOVID-19коронавируспневмонияidiopathic pulmonary hypertensionpulmonary arterial hypertensionCOVID-19coronaviruspneumoniaАвторы декларируют отсутствие внешнего финансирования для проведения исследования и публикации статьиThe authors declare that there is no external funding for the study and publication of the articleReferencesGalie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016. 37(1): 67-119. doi: 10.1093/eurheartj/ehv317Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016. 37(1): 67-119. doi: 10.1093/eurheartj/ehv317Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161:105850. doi: 10.1016/j.rmed.2019.105850Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir. Med. 2020; 161:105850. doi: 10.1016/j.rmed.2019.105850Burger CD, Long PK, Shah MR, McGoon MD, Miller DP, Romero AJ, Benton WW, Safford RE. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014 Nov;146(5):1263-1273. PMID: 24901386; PMCID: PMC4219341, ISSN 0012-3692, doi: 10.1378/chest.14-0193Burger CD, Long PK, Shah MR, McGoon MD, Miller DP, Romero AJ, Benton WW, Safford RE. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014 Nov;146(5):1263-1273. PMID: 24901386; PMCID: PMC4219341, ISSN 0012-3692, doi: 10.1378/chest.14-0193World Health Organization WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 – 11 March 2020. [(accessed on 12 March 2020)]; https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020World Health Organization WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 – 11 March 2020. [(accessed on 12 March 2020)]; https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020Грацианская С. Е., Демченкова А. Ю., Мартынюк Т. В., Веселова Т. Н., Терновой С.К. Клинический случай легкого течения новой коронавирусной инфекции у пациентки с идиопатической легочной гипертензией. Кардиология. 2021;61(10):108-112. doi: 10.18087/cardio.2021.10.n1405Gratsianskaya S.E., Demchenkova A.Yu., Martynyuk T.V., Veselova T.N., Ternovoy S.K. Case report of mild form of a new coronavirus infection in patient with idiopathic pulmonary hypertension. Kardiologiia. 2021;61(10):108-112. (in Russ.) doi: 10.18087/cardio.2021.10.n1405Мартынюк Т.В., Алеевская А.М., Родненков О.В., Зорин А.В., Каспарова А.М., Наконечников С.Н., Чазова И.Е. Ведение пациентов с легочной артериальной гипертензией в условиях пандемии новой коронавирусной инфекции. Евразийский кардиологический журнал. 2020;(2):54-60. doi: 10.38109/2225-1685-2020-2-54-60Martynyuk T.V., Aleevskaya A.M., Rodnenkov O.V., Zorin A.V., Kasparova A.M., Nakonechnikov S.N., Chazova I.E. Management of patients with pulmonary arterial hypertension in the pandemic of a new coronavirus infection. Eurasian heart journal. 2020;(2):54-60. (In Russ.). doi: 10.38109/2225-1685-2020-2-54-60Chapman AR, Bularga A, Mills NL. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020; 141(22):1733-5. doi: 10.1161/CIRCULATIONAHA.120.047008Chapman AR, Bularga A, Mills NL. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020; 141(22):1733-5. doi: 10.1161/CIRCULATIONAHA.120.047008Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518-36. doi: 10.1016/j.jacbts.2020.04.002Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518-36. doi: 10.1016/j.jacbts.2020.04.002Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. doi: 10.1001/jamanetworkopen.2020.5619Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. doi: 10.1001/jamanetworkopen.2020.5619Armand Mekontso Dessap, Florence Boissier, Cyril Charron, Emmanuelle Bégot et. al. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016 May;42(5):862-870. doi: 10.1007/s00134-015-4141-2Armand Mekontso Dessap, Florence Boissier, Cyril Charron, Emmanuelle Bégot et. al. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016 May;42(5):862-870. doi: 10.1007/s00134-015-4141-2Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. (2020). doi: 10.1101/2020.04.06.20050575Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. (2020). doi: 10.1101/2020.04.06.20050575Nuche J., Pérez-Olivares C., Segura de la Cal T., Jiménez López-Guarch C., Arribas Ynsaurriaga F., Escribano Subías P. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev. Esp. Cardiol. (2020). doi: 10.1016/j.recesp.2020.05.028Nuche J., Pérez-Olivares C., Segura de la Cal T., Jiménez López-Guarch C., Arribas Ynsaurriaga F., Escribano Subías P. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev. Esp. Cardiol. (2020). doi: 10.1016/j.recesp.2020.05.028Horn E.M., Chakinala M., Oudiz R., Joseloff E., Rosenzweig E.B. Сould pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020;10. doi: 10.1177/2045894020922799Horn E.M., Chakinala M., Oudiz R., Joseloff E., Rosenzweig E.B. Сould pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020;10. doi: 10.1177/2045894020922799Cal T.S.d.l., Nuche J., López-Guarch C.J., Pérez-Olivares C., Velázquez M., Medrano F.L., Gude M.J.L., Charterina S.A., Ynsaurriaga F.A., Subías P.E. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020. doi: 10.1016/j.arbres.2020.06.004Cal T.S.d.l., Nuche J., López-Guarch C.J., Pérez-Olivares C., Velázquez M., Medrano F.L., Gude M.J.L., Charterina S.A., Ynsaurriaga F.A., Subías P.E. Unexpected favourable course of Coronavirus Disease 2019 in chronic thromboembolic pulmonary hypertension patients. Arch. Bronconeumol. 2020. doi: 10.1016/j.arbres.2020.06.004Fida Charif, Fatima Dakroub, Imad Bou Akl, Mithum Kularatne, David Montani. Pulmonary arterial hypertension and COVID-19: Piecing the puzzle. Respiratory Medicine and Research Volume 84, November 2023, 101053. doi: 10.1016/j.resmer.2023.101053Fida Charif, Fatima Dakroub, Imad Bou Akl, Mithum Kularatne, David Montani. Pulmonary arterial hypertension and COVID-19: Piecing the puzzle. Respiratory Medicine and Research Volume 84, November 2023, 101053. doi: 10.1016/j.resmer.2023.101053Nuche J, Segura de la Cal T, Jiménez López Guarch C, López-Medrano F, Delgado CP-O, Ynsaurriaga FA, Delgado JF, Ibáñez B, Oliver E, Subías PE. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics. 2020;10(8):548. doi: 10.3390/diagnostics10080548Nuche J, Segura de la Cal T, Jiménez López Guarch C, López-Medrano F, Delgado CP-O, Ynsaurriaga FA, Delgado JF, Ibáñez B, Oliver E, Subías PE. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics. 2020;10(8):548. doi: 10.3390/diagnostics10080548Hemnes A.R., Rathinasabapathy A., Austin E.A. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51:1702638. doi: 10.1183/13993003.02638-2017Hemnes A.R., Rathinasabapathy A., Austin E.A. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51:1702638. doi: 10.1183/13993003.02638-2017Kuba K., Imai Y., Rao S. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879. doi: 10.1038/nm1267Kuba K., Imai Y., Rao S. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879. doi: 10.1038/nm1267Araz O. Current Pharmacological Approach to ARDS: The Place of Bosentan. Eurasian J.Med. 2020; 52:81-85. doi: 10.5152/eurasianjmed.2020.19218Araz O. Current Pharmacological Approach to ARDS: The Place of Bosentan. Eurasian J.Med. 2020; 52:81-85. doi: 10.5152/eurasianjmed.2020.19218Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020 Jun 9;323(22):2329-2330. PMID: 32329799. doi: 10.1001/jama.2020.6825Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020 Jun 9;323(22):2329-2330. PMID: 32329799. doi: 10.1001/jama.2020.6825Kabir AA. Anticoagulation is the answer in treating noncritical COVID-19 patients. Open Med (Wars). 2021 Oct 5;16(1):1486-1492. PMID: 34703901; PMCID: PMC8494147. doi: 10.1515/med-2021-0354Kabir AA. Anticoagulation is the answer in treating noncritical COVID-19 patients. Open Med (Wars). 2021 Oct 5;16(1):1486-1492. PMID: 34703901; PMCID: PMC8494147. doi: 10.1515/med-2021-0354

The authors declare that there are no conflicts of interest present.